Alector, Inc. Operating Income
Alector, Inc. (ALEC) reported Operating Income of -$24.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Alector, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$24.39M.
- Alector, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$24.92M.
- Alector, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$39.57M.
- Alector, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$37.61M.
- Alector, Inc. operating income (loss) for fiscal 2025 was -$156.01M.
- Alector, Inc. operating income (loss) for fiscal 2024 was -$145.00M.
- Alector, Inc. operating income (loss) for fiscal 2023 was -$151.74M.
- Alector, Inc. operating income (loss) for fiscal 2022 was -$137.83M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.39M 10-Q · filed 2026-08-06 | -$49.31M 10-Q · filed 2026-08-06 | -$88.88M derived: sum of 3 quarters · filed 2026-08-06 | -$126.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$24.92M 10-Q · filed 2026-05-07 | -$64.48M derived: sum of 2 quarters · filed 2026-05-07 | -$102.09M derived: sum of 3 quarters · filed 2026-05-07 | -$136.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$39.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$77.17M derived: sum of 2 quarters · filed 2026-02-25 | -$111.31M derived: sum of 3 quarters · filed 2026-08-06 | -$156.01M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$37.61M 10-Q · filed 2025-11-06 | -$71.75M derived: sum of 2 quarters · filed 2026-08-06 | -$116.44M 10-Q · filed 2025-11-06 | -$123.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$34.14M 10-Q · filed 2026-08-06 | -$78.83M 10-Q · filed 2026-08-06 | -$86.08M derived: sum of 3 quarters · filed 2026-08-06 | -$134.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$44.70M 10-Q · filed 2026-05-07 | -$51.94M derived: sum of 2 quarters · filed 2026-05-07 | -$100.38M derived: sum of 3 quarters · filed 2026-05-07 | -$145.98M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$55.68M derived: sum of 2 quarters · filed 2026-02-25 | -$101.29M derived: sum of 3 quarters · filed 2026-02-25 | -$145.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$48.43M 10-Q · filed 2025-11-06 | -$94.04M derived: sum of 2 quarters · filed 2025-11-06 | -$137.75M 10-Q · filed 2025-11-06 | -$185.20M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$45.61M 10-Q · filed 2025-08-07 | -$89.31M 10-Q · filed 2025-08-07 | -$136.77M derived: sum of 3 quarters · filed 2025-08-07 | -$187.35M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$43.71M 10-Q · filed 2025-05-08 | -$91.16M derived: sum of 2 quarters · filed 2025-05-08 | -$141.74M derived: sum of 3 quarters · filed 2025-05-08 | -$145.33M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$47.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$98.04M derived: sum of 2 quarters · filed 2025-02-26 | -$101.63M derived: sum of 3 quarters · filed 2025-02-26 | -$151.74M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$50.58M 10-Q · filed 2024-11-06 | -$54.17M derived: sum of 2 quarters · filed 2024-11-06 | -$104.29M 10-Q · filed 2024-11-06 | -$159.72M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$3.59M 10-Q · filed 2024-08-07 | -$53.70M 10-Q · filed 2024-08-07 | -$109.14M derived: sum of 3 quarters · filed 2025-02-26 | -$156.89M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$50.12M 10-Q · filed 2024-05-08 | -$105.55M derived: sum of 2 quarters · filed 2025-02-26 | -$153.30M derived: sum of 3 quarters · filed 2025-02-26 | -$143.83M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$55.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$103.19M derived: sum of 2 quarters · filed 2025-02-26 | -$93.71M derived: sum of 3 quarters · filed 2025-02-26 | -$137.83M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$47.75M 10-Q · filed 2023-11-07 | -$38.27M derived: sum of 2 quarters · filed 2023-11-07 | -$82.40M 10-Q · filed 2023-11-07 | -$138.13M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $9.47M 10-Q · filed 2023-08-03 | -$34.65M 10-Q · filed 2023-08-03 | -$90.38M derived: sum of 3 quarters · filed 2024-02-27 | $35.95M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$44.12M 10-Q · filed 2023-05-04 | -$99.85M derived: sum of 2 quarters · filed 2024-02-27 | $26.48M derived: sum of 3 quarters · filed 2024-02-27 | -$28.85M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$55.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $70.60M derived: sum of 2 quarters · filed 2024-02-27 | $15.28M derived: sum of 3 quarters · filed 2024-02-27 | -$37.36M 10-K · filed 2024-02-27 |
| 2021-09-30 | $126.33M 10-Q · filed 2022-11-08 | $71.00M derived: sum of 2 quarters · filed 2022-11-08 | $18.37M 10-Q · filed 2022-11-08 | -$34.39M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$55.33M 10-Q · filed 2022-08-04 | -$107.96M 10-Q · filed 2022-08-04 | -$160.72M derived: sum of 3 quarters · filed 2023-02-28 | -$214.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$52.63M 10-Q · filed 2022-05-05 | -$105.39M derived: sum of 2 quarters · filed 2023-02-28 | -$159.14M derived: sum of 3 quarters · filed 2023-02-28 | -$205.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$52.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$106.51M derived: sum of 2 quarters · filed 2023-02-28 | -$153.10M derived: sum of 3 quarters · filed 2023-02-28 | -$195.17M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$53.75M 10-Q · filed 2021-11-04 | -$100.34M derived: sum of 2 quarters · filed 2021-11-04 | -$142.42M 10-Q · filed 2021-11-04 | -$174.76M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$46.59M 10-Q · filed 2021-08-03 | -$88.67M 10-Q · filed 2021-08-03 | -$121.01M derived: sum of 3 quarters · filed 2021-08-03 | -$155.16M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | -$42.08M 10-Q · filed 2021-05-05 | -$74.42M derived: sum of 2 quarters · filed 2021-05-05 | -$108.57M derived: sum of 3 quarters · filed 2021-05-05 | -$135.72M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$32.34M 10-K · filed 2020-03-24 | -$66.49M derived: sum of 2 quarters · filed 2020-11-10 | -$93.64M derived: sum of 3 quarters · filed 2020-11-10 | -$114.40M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$34.15M 10-Q · filed 2020-11-10 | -$61.30M derived: sum of 2 quarters · filed 2020-11-10 | -$82.06M 10-Q · filed 2020-11-10 | -$101.08M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$27.15M 10-Q · filed 2020-08-11 | -$47.91M 10-Q · filed 2020-08-11 | -$66.93M derived: sum of 3 quarters · filed 2020-08-11 | -$83.75M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$20.76M 10-Q · filed 2020-05-13 | -$39.78M derived: sum of 2 quarters · filed 2020-05-13 | -$56.59M derived: sum of 3 quarters · filed 2020-05-13 | -$68.82M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | -$19.02M 10-K · filed 2020-03-24 | -$35.83M derived: sum of 2 quarters · filed 2020-03-24 | -$48.06M derived: sum of 3 quarters · filed 2020-03-24 | -$57.29M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$16.82M 10-K · filed 2020-03-24 | -$29.05M derived: sum of 2 quarters · filed 2020-03-24 | -$38.27M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$12.23M 10-K · filed 2020-03-24 | -$21.46M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$9.22M 10-K · filed 2020-03-24 | |||
| 2017-12-31 | -$32.68M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |